Psychometric analysis of the Children's Depression Rating Scale-Revised (CDRS-R) in a large international study of pediatric Major Depressive Disorder (MDD)

Depression is a serious mental health condition that affects people of all ages, including children and teenagers. It can cause deep sadness, loss of interest in activities, trouble sleeping, and difficulty concentrating. In the United States and around the world, many young people suffer from depression, and finding effective treatments is very important. However, clinical trials testing antidepressant medications in children often fail to show that the drug works better than a placebo (a pill with no active medicine). This is true even for drugs that have been proven to help adults with depression.

One possible reason for these failures is the way depression is measured in children during clinical trials. The Children's Depression Rating Scale-Revised (CDRS-R) is the main tool used to measure how depressed a child is and whether the child's symptoms improve during treatment. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) consider this the gold standard for these studies. But researchers are now asking whether this tool is doing a good job of detecting real changes in children’s depression, and whether it might be one reason many pediatric antidepressant trials fail.

In this research, we will study how well the CDRS-R works by analyzing data from a series of depression studies in children and teens conducted by the pharmaceutical company Lundbeck. These studies tested a drug called vortioxetine for pediatric depression. The company has agreed to share detailed, unblinded patient level (fully transparent) data from these studies with us through Vivli.

We will look closely at each question in the CDRS-R to find out how much it contributes to measuring a child's level of depression, how well it detects changes over time, and whether it helps show the difference between a real drug and a placebo. This may help us identify whether the scale is too long or includes questions that aren’t helpful. It could also show us whether the tool works better or worse for certain age groups or in different regions.

Our goal is to make sure the tools used in pediatric depression research are accurate, reliable, and able to detect when a treatment truly works. Improving these tools could help bring better treatments to young people who need them.